Introduction
Glycogen is a highly branched glucose polymer synthesized by two enzymes: (i) glycogen synthase (GYS), which attaches glucose to nascent linear chains of glycogen, and (ii) the glycogen-branching enzyme (GBE), which attaches a short branch of ∼4 glucose units to the linear chain. The absence of GBE causes glycogen storage disease type IV (GSD IV, OMIM 232500). GSD IV is an autosomal recessive disorder typically diagnosed histologically by the accumulation of a poorly branched form of glycogen known as polyglucosan (PG). In GSD IV, PG mainly accumulates in the liver, heart, skeletal muscle and central nervous system, tissues that have high metabolic activity. However, GSD IV is a very heterogeneous disorder, affecting different organs at different ages, with visceral and/or neuromuscular involvement. Based primarily upon the amount of residual GBE activity, there are clinically distinguishable forms of the disease, including an early-onset form associated with a complete loss of enzyme activity, a juvenile or adult-onset form associated with partial activity and a clinically distinct adult-onset disease that is known as adult polyglucosan body disease (APBD). The infantile form of the disease is known as Andersen's disease and is typically due to the absence of GBE activity. The clinical features include failure to thrive, hepatosplenomegaly and progressive liver cirrhosis, typically leading to death in early childhood (1) . Residual GBE activity causes different disease symptoms at different ages from fetus to adult; therefore, presentation of the disease can be separated into four groups based upon the age at onset: perinatal, presenting as fetal akinesia and perinatal death; congenital, with hypotonia and death in early infancy; childhood, with myopathy and/or cardiomyopathy; and adult, with isolated myopathy or APBD.
APBD was first described in 1971 (2) and is characterized clinically by progressive upper and lower motor neuron dysfunction, marked distal sensory loss (mainly in the lower extremities), early neurogenic bladder, cerebellar dysfunction and cognitive problems (3) (4) (5) (6) (7) (8) . The typical neuropathologic findings are numerous large PG bodies (PGB) in the peripheral nerves, cerebral hemispheres, basal ganglia, cerebellum and spinal cord (5, 7, 9, 10) . Isolated cases of PG myopathy without peripheral nerve involvement have also been described (11, 12) .
Currently, no treatment is available for GSD IV, although liver transplantation has been performed in patients with apparently isolated liver involvement (13) . Two naturally occurring animal models of GBE deficiency, American quarter horses and Norwegian forest cats, are not practical laboratory animals (14, 15) . Mouse models generated either by homologous recombination or chemical germline mutagenesis that leads to the complete elimination of GBE activity only exhibit early-onset GSD IV (16) . Currently, the best mouse model of GBE deficiency for adult-onset GSD IV is a mouse with reduced Gbe1 expression due to insertion of a gene cassette into the otherwise intact gene (17) . We have developed a new mouse model of GBE deficiency by knocking in via homologous recombination the most common human GBE1 mutation ( p.Y329S) found in Ashkenazi Jewish patients. We developed this model in order to better understand the pathogenesis of the disease and to test therapeutic strategies.
Results

Generation of mice with p.Y329S mutation in GBE
A mouse model of GBE deficiency was generated by knocking in the p.Y329S mutation into exon 7 and introducing flippase recognition target (FRT) recombination sequences upstream and downstream of the mouse Gbe1 exon 7 via homologous recombination (Fig. 1A) . Since the p.Y329S mutation is linked to an adjacent 50-base-pair (bp) FRT sequence (indicated by open triangles in Fig. 1A ), we used this size difference to genotype by polymerase chain reaction (PCR) wild-type, heterozygous or homozygous mice. Gbe1 +/ys-neo animals were first bred to Cre-expressing mice in order to remove the PGK-neomycin cassette, or they were intercrossed to generate Gbe1 ys-neo/ys-neo homozygous mice harboring both the p.Y329S mutation and the PGK-neomycin cassette (flanked by the gray triangles that represent LoxP consensus sequences in Fig. 1A ). PCR analysis using primers Figure 1A . Elimination of exon 7 by breeding to mice expressing an flp-e transgene yielded a severe Andersen disease model, as we reported previously (18) . Excision of PGK-neomycin cassette was detected by PCR analysis using primers that can amplify either a 400 bp-long cassette and part of intron 7 or a 300 bp-long fragment containing part of intron 7, and FRT and lox-p consensus sequences (data not shown). In order to confirm the homozygous p.Y329S mutation in exon 7, total muscle RNA isolated from Gbe1 ys/ys mice was reverse transcribed and amplified by PCR. The PCR primers were designed to amplify an 810 bp wild-type Gbe1 mRNA fragment spanning exons 4-10 that are 54 kb apart in genomic DNA. Reverse transcriptase-polymerase chain reaction (RT-PCR) products were sequenced to demonstrate the homozygous p.Y329S mutation (Fig. 1C) .
GBE-deficient embryos are stillborn after a normal gestation
Removing exon 7 by Flpe recombination leads to loss of GBE activity (18) . Complete loss of GBE activity causes death in utero and still birth in humans (16, 19, 20) . Gbe1 −/− mice likewise die at or soon after birth. The mice are comparable with heterozygous and wild-type littermates in terms of size and appearance after birth ( Fig. 2A) ) have a significantly reduced but still detectable amount of GBE protein in muscle (Fig. 2B) . Reduced GBE protein due to the p.Y329S mutation and the presence of the PGK-neomycin cassette causes early death in homozygous mice. The Effect of the p.Y329S mutation on GBE and glycogen content
It has previously been shown in humans that the p.Y329S substitution decreases GBE activity to 20% of healthy controls and leads to reduced branching of glycogen (8) . The murine GBE protein is 98% identical to human GBE; therefore, we measured GBE activity in wild-type, Gbe1 ys-neo/ys-neo and Gbe1 ys/ys animals. Unlike exon 7 knockout animals, both Gbe1 ys -neo/ys-neo and Gbe1 ys/ys animals have a low but detectable amount of residual GBE activity, while removal of the PGK-neomycin cassette increases the residual GBE activity almost 2 fold in tissues studied (Table 1) . Next, we determined the glycogen content in muscle tissue among the different genotypes of Gbe1 mice. Although GBE takes part in the synthesis of glycogen and mediates the proper branching, in all GBE-deficient mice, we found that brain, heart, liver and muscle glycogen content was significantly greater than in controls, reflecting a greater accumulation of the abnormal PG (Table 1 ) despite a comparable amount of GYS protein in muscles, as determined by western blotting (Fig. 2B ).
Low GBE activity leads to PG formation in tissues
Clinically, GSD IV is diagnosed by the presence of poorly branched glycogen that is resistant to diastase (alpha amylase) digestion. Therefore, we examined the accumulation of diastase-resistant PG in multiple organs from 1-year-old Gbe1 ys/ys mice. Because the juvenile and adult forms of GSD IV are typically a neuromuscular disorder, we examined brain and muscle samples first. 
Gbe1 ys/ys neonates contain detectable PG
The pathogenic mechanism of GBE deficiency is still a subject of debate. Since we generated an animal model with the most common human GBE1 mutation, we examined whether younger animals that do not show any outward signs of the disease still have detectable PGB in tissues. Therefore, we tested whether glycogen is present in fetal tissues. Due to size limitations, we used wholemount embryo sections and assessed the glycogen content by histochemistry. Whole embryos were fixed in 10% buffered formaldehyde, embedded in paraffin, sectioned and briefly treated with diastase to digest normal glycogen. Sections were then stained with periodic Schiff base (PAS). Limited digestion with diastase degrades almost all structurally normal glycogen, while longer and poorly branched PG remains intact and thus stains with PAS. Whole cross sections were examined by light microscopy. Sections of choroid plexus, brain stem, muscle, and dorsal root ganglion cells, liver, and epithelial cells of the brain had PGB (Fig. 4A-H, indicated by arrows) . However, the heart (not shown) and the brain cerebral cortex did not exhibit any accumulation of PGB ( Fig. 4I and J) .
Accumulated PGB are ubiquitinylated
Ubiquitinylation is the intracellular targeting mechanism that marks molecules or organelles for proteosomal or lysosomal degradation (22) . Since PG is a poorly branched molecule, its abnormal structure may allow it to escape from the surveillance of ubiquitinylating enzymes that mark glycogen and its protein scaffold for lysosomal degradation, similar to the interruption of glycogen particle ubiquitinylation observed in Lafora's disease (LD) (23) . In order to study the ubiquitinylation status of PG in Values represent the mean ± SD, P < 0.001 (n = 6 for each group).
GBE-deficient mice, heart and skeletal muscle samples were prepared from 1-year-old mice and examined for PGB accumulation as described above, together with immunohistochemistry. Liver, heart and skeletal muscle sections exhibit strong staining of PGB with anti-ubiquitin antibodies, which is absent in control liver samples. However, not all PGB co-stained with ubiquitin in the muscle and the heart (Fig. 5E-H) , suggesting that PG-associated proteins can selectively be ubiquitinylated but can also remain intact in the cell protected from lysosomal degradation.
Discussion
GBE deficiency is a rare disorder with a very heterogeneous clinical presentation that appears to be determined in part by the degree of residual enzyme activity. Complete loss of activity in humans is lethal either in the third trimester of pregnancy or in infancy (Andersen's disease), while mutations that reduce enzyme activity cause juvenile-or adult-onset disease. Juvenileonset disease typically exhibits liver and/or heart involvement, while adult-onset disease is mainly a neuromuscular disorder and may be misdiagnosed as amyotrophic lateral sclerosis, multiple sclerosis or Alzheimer's disease (5, 7, 8, 24) . Here, we describe a series of mouse models of GSD IV that accurately recapitulate the histological, biochemical and clinical spectrum of disease. Deletion of exon 7 eliminates enzyme activity in all tissues and thus is a model of Andersen's disease. In contrast, decreasing the expression of the Gbe1 via transcriptional interference by the reverse-oriented PGK-neomycin cassette and/or introduction of the p.Y329S mutation found in the Ashkenazi Jewish population both lead to hypomorphic alleles with residual enzyme activity and to a later onset disease ( Fig. 2A , and Supplementary Material, Fig. S1 ), but with pronounced accumulation of PGB. Exon 7 of Gbe1 contains the c-terminus of the alpha amylase domain and the linker region that connects the alpha amylase domain to the glycosyl-transferase domain. Since exon 7 encodes an in-frame 70-amino-acid polypeptide, we have shown that its deletion leads to an unstable protein. These pups are born full term but fail to survive. Could this be due to pathogenic features of PG or, as has been proposed (25) , to secondary reduction of GYS activity? If PG has a toxic effect, we should observe the same severe phenotype in animals with the p.Y329S mutation since their tissues contain more PGB than exon 7-deleted animals. We can potentially explain the lack of viability by the absence of digestible glycogen in the complete GBE deficiency state. On the other hand, the p.Y329S mutation decreases enzyme activity but still allows for the formation of poorly branched glycogen, which can provide free glucose better than unbranched glycogen and presumably enough glucose for the newborn after birth. However, a lack of glycogen in tissues has been reported previously in the absence of GYS (26, 27) , which, unlike GBE, has two isoforms: the liver-specific GYS2 and GYS1 expressed in other tissues. GYS2-deficient mice have near-normal development, whereas 90% of GYS1-deficient mice die after birth. Thus, given that there is a single Gbe1 locus, Gbe1 −/− mice mimic the course of GYS1-deficient mice, but, like GYS2-deficient mice, they also lack significant amounts of liver glycogen in the presence of readily detectable PGB. Hence, the early death of GBE-deficient mice is not likely to be due to the absence of structurally normal glycogen in the liver, but rather to its deficiency in other tissues. Although we did not observe hydropic embryos or left ventricular non-compaction, the hearts of Gbe1 −/− mice appear to have disrupted myocardial architecture in association with widespread PGB accumulation (17) . Future studies in Gbe1 −/− mice will address the molecular basis for this structurally abnormal myocardium. Although low GBE activity caused by the PGK-neomycin cassette and the p.Y329S mutation in newborn pups does not cause complications immediately after birth, the residual enzyme activity determines the life span of the mice. This clearly indicates that accumulated PG begins to affect muscle and nerve functions causing premature death, similar to cases with more severe mutations causing the juvenile form of GSD IV (19) .
The PGK-neomycin cassette used for positive selection in mouse embryonic stem (ES) cells alters the expression of Gbe1. Both GBE activity assays and western blotting have shown that transcription of the Gbe1 gene is reduced. This has generated a phenotype similar to the juvenile and adult forms of GSD IV. Point mutations that decrease enzyme activity, such as Y329S Thus, in order to manifest the disease, the enzyme activity must be <50% (28) . Previously there were rare case reports of manifesting heterozygotes, with clinical features occurring in the sixth decade of life (29); however, these patients were recently shown to have a deep intronic mutation not detected by standard DNA sequencing (30) . In aged humans and animals, PG-like bodies known as corpora amylacea can be seen in white matter and axons, but the relationship to GBE activity remains unexplored (31) . Gbe1 +/ys mice are being systematically aged to determine whether a reduction in GBE can lead to the formation of PGB in the brain. PG is also a component of the Lafora bodies that lead to juvenile myoclonic epilepsy (Lafora's disease). Lafora's disease is an autosomal recessive disorder with typical disease onset in teenage years and progressive myoclonic epilepsy leading to death within a decade. The Lafora bodies are found in the perikarya of neurons and other cell types. The pathogenic mechanism of LD does not involve the glycogenolytic enzymes per se but is caused by the functional loss of regulatory enzymes that may indirectly affect glycogenolytic enzymes (32) . Two genes causing LD, EPM2A and NHLRC1 (EPM2B), have been identified (33, 34 ). An animal model of LD has also been described; however, the exact mechanism of PG formation is not well understood (35) (36) (37) . Interestingly, breeding GYS1-deficient mice to LD mice did prevent LD and decrease the pathogenicity of PG in disease (38) .
Although we have shown that PGB accumulating in the liver, heart and muscle are ubiquitinylated, the PG is not degraded, perhaps because the degradation mechanisms are overwhelmed or impaired. Ubiquitination is a signal for proteosomal or lysosomal degradation, and ubiquitin-rich inclusions are seen in other diseases (39) . In Gbe1 ys/ys mice heart and brain tissues, all PGB were ubiquitinylated; however, skeletal muscle tissue showed some PGB free of ubiquitin. This suggests that either there is selective ubiquitinylation in muscle or that newly synthesized PG has not yet been ubiquitinylated. The former model, selective ubiquitinylation of such large molecules, is not likely. Second, as muscle has a very high turnover of glycogen, the latter model, that newly synthesized PG are not ubiquitinylated, appears more tenable. Although ubiquitination was identified as a marking mechanism in order to degrade molecules or organelles, it also activates or inactivates marked proteins similar to phosphorylation. Ubiquitylated proteins in PGB may have different functions, including intracellular trafficking of glycogen and/or activation/deactivation of associated proteins. We will use this new model to further study the mechanism of ubiquitylation of PGB. In summary, we have generated a novel mouse model of APBD using the most common mutation found in the Ashkenazi Jewish population. Similar to APBD patients, PGB accumulate in muscle, brain, heart and liver and cause premature death. Stiffness in the hind limbs after 1 year of age is consistent with the natural history of the disease ( please see the Supplementary Material, Video S1) (8) . As affected mice cannot use their hind limbs, further studies are needed to address whether the problem is a combination of upper and/or lower motor neuron dysfunction. This model can also be used to develop possible treatment strategies that enhance the physiologic degradation of PG. The recent report that enzyme replacement therapy with recombinant acid α-glucosidase may benefit glycogen debranching deficient patients (40) suggests the possibility of a similar approach for GBE deficiency. Therefore, this mouse model will serve as a useful tool for examining the biology of PGB formation and its degradation, and as a means for testing possible therapeutic approaches.
Materials and Methods
Knock-in of p.Y329S mutation into Gbe1
The Gbe1 targeting vector was assembled by PCR-amplified and restriction enzyme-digested fragments from ES 129Sv mouse DNA. A 1020 bp NheI fragment containing exon 7 was cloned in pUC18 vector and modified by inserting FRT oligos upstream and downstream of exon 7. TAC to TCC change corresponding to 329th codon was introduced by site-directed mutagenesis. A phosphoglycerate kinase (PGK) promoter-neomycin resistance cassette flanked by loxP sites was cloned 5′ to the FRT site downstream of seventh exon for positive drug selection. The final construct contained a 2.1 kb 5′ short recombination arm composed of a portion of intron 6, the upstream FRT site followed by exon 7, the PGK-neomycin resistance cassette for positive selection flanked by loxP sites, and the FRT site on the 3′ end, followed by a 6.5 kb-long recombination arm spanning intron 7. Finally, a MC1-driven thymidine kinase-1 gene was incorporated into the plasmid for negative selection against non-homologous recombination (see Fig. 1 ). All of the junctions in the final construct were confirmed by sequencing and restriction enzyme digestion. The NotI-linearized vector was electroporated into AB2.2 ES cells by the mouse transgenic core facility at Baylor College of Medicine, Houston, TX. Selection of ES cells used Ganciclovir ® as a negative selection drug and G418 for positive selection. Cells surviving in the presence of G418 were screened by PCR for appropriately targeted integration. Positive ES cell clones were confirmed by additional PCR and Southern analyses to contain the two FRT sites to be correctly targeted at both the 5′ and 3′ ends of exon 7. The ES cells were used to generate chimeric mice by blastocyst microinjection, and these mice bred to confirm transmission of the targeted allele.
Genotyping wild-type and Cre-recombined alleles Tail DNA was isolated by standard techniques and the Gbe1 locus PCR amplified using primers, 5′ AGC TTT GGT TAT AGA CGA ATC ACT, b, 5′ GTC TAT GTC CAG CAC AGT ATT AAG GA and c.-5′ TCC TGA AAT GGG ATA TAT GGG ATA TG. PCR reaction was prepared as described in the vendor's protocol (New England BioLabs) Thermal cycles were programmed for touchdown PCR as follows: initial 5 min denaturation at 95°C followed by touchdown PCR cycles with the following steps: denaturation at 95°C for 30 min, annealing at 65°C decreasing 0.5°C every cycle for the next 20 cycle and 72°C extension. After the touchdown protocol, 20 cycles of regular PCR was carried out starting with 95°C denaturation for 30 s, annealing at 55°C for 30 s and primer extension at 72°C for 45 s. Amplified fragments are separated on 2% agarose gel and photographed.
Preparation of samples for biochemical analyses
Four to six months old adult mice and 4-month-old female mice on the 17th day of pregnancy were anesthetized by IsoThesia™ (Butler Animal Health Supply Dublin, OH) inhalation and 
Western analysis
For western analysis, 30 µg of tissue homogenate was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were transferred to nitrocellulose membranes and incubated with monoclonal antibodies raised against human GBE and GYS1 (Origene Rockville, MD). Detection was achieved with horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence.
Quantification of glycogen
Glycogen content was estimated by measuring glucose released by amyloglucosidase digestion of ethanol-precipitated glycogen from muscle or liver tissue, as described (41) . Samples of frozen muscle and liver tissue (∼30-60 mg) were boiled in 200 µl of 30% (wt/vol) KOH for 30 min with occasional shaking. After cooling, 67 µl of 0.25 M Na 2 SO 4 and 535 µl of ethanol were added. Next, samples were centrifuged at 14 500g for 20 min at 4°C to collect glycogen. The glycogen pellet was suspended in water (100 µl), 200 µl of ethanol was added and centrifugation as described above was used to harvest glycogen. This ethanol precipitation step was repeated, and the glycogen pellet was dried in a Speed-Vac. Dried glycogen pellets were suspended in 100 µl of amyloglucosidase [0.3 mg/ml in 0.2 M sodium acetate ( pH 4.8)] and incubated at 37°C for 3 h to digest glycogen. To determine the glucose concentration in the samples, an aliquot (5 µl) of digested glycogen was added to 95 µl of a solution containing 0.3 M triethanolamine ( pH 7.6), 0.4 m MgCl 2 , 0.9 m nicotinamide adenine dinucleotide phosphate, 1 m ATP and 0.1 µg/ml glucose-6-phosphate dehydrogenase. The absorbance at 340 nm was read before and after the addition of 0.1 µg of hexokinase.
Alanine and aspartate transaminase and creatine kinase assays
Five microliters of serum, obtained from six 1-year-old male wild-type and Gbe1 ys/ys mice, were used in ALT, AST (Genzyme corp USA) and CPK (Pointe Scientific, Canton, MI) enzyme assays. Serum was separated from the blood clot. Blood was drawn by cardiac puncture right after carbon dioxide asphyxiation. Enzyme activities were measured by spectrophotometry as described by the supplier.
Glycogen-branching enzyme activity
GBE activity was assayed as described by Tay et al. (20) . Briefly, frozen tissue samples were homogenized in all-glass homogenizers in nine volumes of 5 m Tris, 1 m EDTA, 5 m mercaptoethanol, pH 7.2 and centrifuged at 9200g for 10 min. Branching enzyme activity was measured by an indirect assay based upon incorporation of radioactive glucose-1-phosphate (PerkinElmer Life and Analytical Sciences, Boston, MA) into glycogen by the reverse activity of phosphorylase a (Sigma St. Lois, MO) as an auxiliary enzyme. At 30, 45 and 60 min time intervals, 5 µl of reaction mix was spotted on Whatman® Number 5 qualitative filter paper (Maidstone, UK). Unincorporated glucose-1-phosphate was washed for 15 min using three changes of 66% v/v ethanol. Glycogen-bound radioactive glucose-1-phosphate was quantified by liquid scintillation counter (Packard Instruments, Boston, MA).
Tissue staining and histochemistry
Tissue sections were prepared from 4-month-old mice, fixed in 10% formalin and embedded in paraffin. Slices of 5 µm were deparaffinized, and one slide of each sectioned block was treated with 40 ml of 5 µg/ml α-amylase (Sigma) for 25 s in a microwave oven set to 600 watts, the slides washed with deionized water, and oxidized with 0.5% periodic acid for 5 min, stained with Schiff reagent for 15 min and then counterstained in hematoxylin for 15 min and rinsed in tap water. The slides were then examined by light microscopy (Nikon Eclipse90i, Melville, NY). Gomori trichrome staining was performed at the Columbia University pathology services.
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